At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Randomized, Partially Fixed-Sequence, 4-Period Crossover Study to Assess the Pharmacokinetics After Administration of the DFC and OCT Formulations and the Food Effect on the OCT Formulation of MK-0941 in Patients With Type 2 Diabetes
In Brief
A Phase 1 clinical trial evaluating 10 mg MK-0941 DFC (fasted), 10 mg MK-0941 OCT (after meal), and 2 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 18 participants.
Detailed Summary
A study to compare the pharmacokinetics (PK) of the dry filled capsule (DFC) \& oral compressed tablet (OCT) formulations of MK-0941-009 \& to assess the effect of food on the OCT formulation.
Study Details
Timeline
Interventions
single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state